Ventilation and blood-flow patterns in adults with asthma
Official title: Ventilation and Perfusion in Individuals With Asthma
Run by University of Miami · NCT07426458 · Data updated 2026-11-12
This trial will test whether inhaled corticosteroids and quick-acting albuterol change how air and blood move through the lungs of adults with asthma.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami, Florida) |
| Status | Recruiting |
| Started | April 27, 2026 |
| Main results expected | April 2028 |
| Study ends | April 2028 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT07426458 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18–75 with physician-diagnosed asthma, baseline FEV1 <80% predicted with ≥10% reversibility after bronchodilator, and on a stable inhaled corticosteroid regimen for at least three months.
✕Probably not a fit
People with very severe obstruction (FEV1 <50%), current smokers or those with >10 pack-year history, recent respiratory infection, pregnancy or breastfeeding, intolerance to the study drugs, or recent use of systemic steroids or beta-blockers are unlikely to be eligible or to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 4 interventional study uses radiographic imaging to measure regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH) in adult asthma patients. Participants are adults aged 18–75 with physician-diagnosed asthma, baseline FEV1 under 80% of predicted with ≥10% reversibility, and who have been on a stable inhaled corticosteroid dose for at least three months. The protocol acquires imaging around administration of fast-acting albuterol and an albuterol–budesonide intervention to detect regional changes in ventilation and perfusion. Major exclusions include current smokers or heavy past smokers, recent respiratory infection, very low lung function (FEV1 <50%), pregnancy or breastfeeding, and intolerance to the study medications.
Why it matters
Potential benefit: If successful, the results could clarify how inhaled steroids and bronchodilators alter regional lung ventilation and perfusion, which may help tailor treatments for people with asthma.
How similar studies have gone: Previous imaging studies using regional ventilation measures and bronchodilator challenges have shown measurable changes, so the imaging approach has precedent though combining long-term ICS context with FABA responses may be less studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Physician diagnosis of asthma * Baseline Forced Expiratory Volume in 1 Second (FEV1) \< 80% of predicted, with reversibility (10%) on post-bronchodilator spirometry * Adults, 18-75 years of age * Long-term inhaled controller medication consisting of or including an Inhaled corticosteroids (ICS) at a steady dose for at least 3 months before enrollment Exclusion Criteria: * Current cigarette smoking or a past history of \>10 pack-year smoking * Current nicotine vaping * Pregnant and breast-feeding women * Respiratory infection within 4 weeks of proposed study date * Forced Expiratory Volume in 1 Second (FEV1) \< 50% * Inhaled corticosteroids (ICS)/fast-acting beta agonist (FABA) intolerance * Use of beta-blockers * Use of systemic glucocorticosteroids or oral methyl-xanthines within 30 days of planned study visit.
Where it's running
-
University of Miami - Converge Miami
Miami, Florida, United States Recruiting
Study contacts
- Principal investigator: Trishul Siddharthan, MD — University of Miami
- Study coordinator: Maria McCoy
- Email: mcm456@med.miami.edu
- Phone: 305-243-2568
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations
This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.
-
Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma
This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)
A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.